NCT03223727View on ClinicalTrials.gov

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 30, 2015

Primary Completion Date

February 3, 2022

Study Completion Date

February 3, 2023

Conditions
Prostate Cancer MetastaticBone Metastases
Interventions
DIAGNOSTIC_TEST

Blood tests

Blood tests for several bone markers (see summary)

Trial Locations (2)

1066CX

The Netherlands Cancer Intitute, Amsterdam

Unknown

Franciscus Gasthuis & Vlietland, Rotterdam

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03223727 - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223 | Biotech Hunter | Biotech Hunter